BioCentury | Mar 3, 2016
Targets & Mechanisms

Targeting TMP

...another common drug target for cancers, as well as for bacterial infections. AstraZeneca markets trimetrexate glucuronate...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Infectious disease

...inhibitor from Biota Holdings Ltd. and GlaxoSmithKline plc, is marketed for the same indication. Neutrexin trimetrexate...
BioCentury | Sep 3, 2002
Strategy

MedImmune's pipeline

...Chemoprotection Mkt CytoGam CMV immune globulin CMV Mkt RespiGam RSV immune globulin RSV Mkt Neutrexin trimetrexate...
BioCentury | Sep 3, 2002
Strategy

Back to School 2002: The sweet spot

...added three marketed products - Ethyol amifostine chemoprotectant, Hexalen altretamine for ovarian cancer, and NeuTrexin trimetrexate...
BioCentury | Dec 10, 2001
Strategy

MEDI-AVIR pipeline

...and neck cancers Marketed MEDI Ethyol Prevent xerostomia following radiation therapy Marketed; Phase II MEDI NeuTrexin...
BioCentury | Dec 10, 2001
Strategy

MEDI-AVIR pipeline

...and neck cancers Marketed MEDI Ethyol Prevent xerostomia following radiation therapy Marketed; Phase II MEDI NeuTrexin...
BioCentury | May 24, 1999
Clinical News

NeuTrexin trimetrexate glucuronate: Phase III data; marketed to treat Pneumocystis carinii pneumonia

...European Phase III trial showed a median survival time of 12.9 months for patients receiving NeuTrexin...
...in the first half of 2000. U.S. Bioscience Inc. (UBS), West Conshohocken, Penn. Product: NeuTrexin trimetrexate glucuronate...
BioCentury | May 24, 1999
Tools & Techniques

Hoping to join the cocktail party

...expectations in an interim analysis of one of its two Phase III trials of NeuTrexin trimetrexate...
...a statistically significant survival benefit. Overall, median survival time was 12.9 months for patients receiving NeuTrexin...
...of biomodulation with NeuTrexin, comparing 500 mg/m2 5-FU plus leucovorin plus either NeuTrexin or placebo. NeuTrexin...
BioCentury | Mar 22, 1999
Company News

Alza, U.S. Bioscience deal

...U.S. co-promotion agreement with AZA for UBS's Hexalen altretamine to treat ovarian cancer and NeuTrexin trimetrexate glucuronate...
BioCentury | Mar 22, 1999
Strategy

Three's a crowd

...NeuTrexin trimetrexate to treat moderate-to-severe Pneumocystis carinii pneumonia. see BioCentury, Oct. 6, 1998). "Hexalen and NeuTrexin...
...they deserve more attention." UBS said it plans to expand its sales force to market NeuTrexin...
...the 1996 agreement, the companies had formed a 60-person sales force to market Hexalen and NeuTrexin...
Items per page:
1 - 10 of 31